Abstract
The limitations of current anti-retroviral therapies (ART) and the lack of a valid anti-HIV-1 vaccine candidate underscore the need for new therapeutic concepts aiming at the eradication of HIV-1, which represents at the same time an ideal goal and a major challenge for AIDS research. At present, this aim is unattainable due to the existence of cellular and anatomical reservoirs of persistent infection. Memory CD4+ T cells comprise the largest pool of cells harboring silent, stably integrated HIV-1, which remains undetected by the immune system and refractory to conventional anti-retroviral drugs. The eradication of latent HIV-1 reservoirs will require new, potent and specific therapeutic strategies, which in turn must rely upon a deeper understanding of HIV-1 latency. To facilitate the advancement of our knowledge in this new area of research, several in vitro models of HIV-1 latency in CD4+ T cells have been established. Here, we dissect and critically compare the rationale behind each experimental approach. Furthermore, we outline new avenues of research that will benefit from these models, including the push toward the development of new classes of viral eradication drugs.
Keywords: HIV-1, latency, in vitro models, HAART, CD4+ T CELLS, Cell line-based models, RNA, proviruses, ANALYSIS, co-stimuli, infection
Current HIV Research
Title: Models of HIV-1 Persistence in the CD4+ T Cell Compartment: Past, Present and Future
Volume: 9 Issue: 8
Author(s): Mudit Tyagi and Fabio Romerio
Affiliation:
Keywords: HIV-1, latency, in vitro models, HAART, CD4+ T CELLS, Cell line-based models, RNA, proviruses, ANALYSIS, co-stimuli, infection
Abstract: The limitations of current anti-retroviral therapies (ART) and the lack of a valid anti-HIV-1 vaccine candidate underscore the need for new therapeutic concepts aiming at the eradication of HIV-1, which represents at the same time an ideal goal and a major challenge for AIDS research. At present, this aim is unattainable due to the existence of cellular and anatomical reservoirs of persistent infection. Memory CD4+ T cells comprise the largest pool of cells harboring silent, stably integrated HIV-1, which remains undetected by the immune system and refractory to conventional anti-retroviral drugs. The eradication of latent HIV-1 reservoirs will require new, potent and specific therapeutic strategies, which in turn must rely upon a deeper understanding of HIV-1 latency. To facilitate the advancement of our knowledge in this new area of research, several in vitro models of HIV-1 latency in CD4+ T cells have been established. Here, we dissect and critically compare the rationale behind each experimental approach. Furthermore, we outline new avenues of research that will benefit from these models, including the push toward the development of new classes of viral eradication drugs.
Export Options
About this article
Cite this article as:
Tyagi Mudit and Romerio Fabio, Models of HIV-1 Persistence in the CD4+ T Cell Compartment: Past, Present and Future, Current HIV Research 2011; 9 (8) . https://dx.doi.org/10.2174/157016211798998754
DOI https://dx.doi.org/10.2174/157016211798998754 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
HIV Vaccine Development.
The development of a safe and effective vaccine that impedes HIV-1 transmission and/or limits the severity of infection remains a public health priority. The HIV-1/AIDS pandemic continues to have a disproportionate impact on vulnerable and under-served communities in the USA and globally. In the USA, minority communities that have relatively ...read more
Lymphomas in People Living with HIV (PLWH)
In the era of combined antiretroviral therapy (cART), the incidence of lymphoma among people living with HIV (PLWH) surpassed Kaposi's sarcoma in 2011, becoming the most common AIDS-defining malignancy. The annual incidence rate ranges approximately from 100 to 300 per 100,000 individuals with HIV infection as the population denominator, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Exploring the Nucleolar Proteome: Novel Concepts for Chaperone Trafficking and Function
Current Proteomics Anticancer Mechanisms of Bioactive Peptides
Protein & Peptide Letters P53 Family: At the Crossroads in Cancer Therapy
Current Medicinal Chemistry Modulation of Calcium Signaling in Glioblastoma Multiforme: A Therapeutic Promise for Natural Products
Mini-Reviews in Medicinal Chemistry Sildenafil in Combination Therapy against Cancer: A Literature Review
Current Medicinal Chemistry Surface Plasmon Resonance Imaging Sensor for Cathepsin Determination Based on Immobilized Cystatin
Protein & Peptide Letters In Vivo Application and Tracking of Baculovirus
Current Gene Therapy Prodrugs in Genetic Chemoradiotherapy
Current Pharmaceutical Design Targeting Glia Cells: Novel Perspectives for the Treatment of Neuropsychiatric Diseases
Current Neuropharmacology Blockade of Neoangiogenesis, a New and Promising Technique to Control the Growth of Malignant Tumors and their Metastases
Current Vascular Pharmacology Mechanism Research of PZD Inhibiting Lung Cancer Cell Proliferation, Invasion, and Migration based on Network Pharmacology
Current Pharmaceutical Design Experimental Models for Evaluation of Nanoparticles in Cancer Therapy
Mini-Reviews in Medicinal Chemistry Innate Immune Receptors and IRF Family Transcription Factors
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Light Chain LC and TAT-EGFP-HCS of Botulinum Toxin Expression and Biological Function <i>in vitro</i> and <i>in vivo</i>
Current Proteomics Stem Cell Differentiation Stage Factors from Zebrafish Embryo: A Novel Strategy to Modulate the Fate of Normal and Pathological Human (Stem) Cells
Current Pharmaceutical Biotechnology Prospects of Bacteriotherapy with Nanotechnology in Nanoparticledrug Conjugation Approach for Cancer Therapy
Current Medicinal Chemistry Inhibition of NF-κB and Proteasome Activity in Tumors: Can We Improve the Therapeutic Potential of Topoisomerase I and Topoisomerase II Poisons
Current Pharmaceutical Design PI-3 Kinase-PTEN Signaling Node: An Intercept Point for the Control of Angiogenesis
Current Pharmaceutical Design Brain Tumor Detection and Classification by Hybrid CNN-DWA Model Using MR Images
Current Medical Imaging System Models, Assays and Endpoint Parameters to Evaluate Anticancer Compounds During Preclinical Screening
Current Medicinal Chemistry